US 8993519
Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
granted A61KA61K38/193A61K38/38
Quick answer
US patent 8993519 (Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K38/193, A61K38/38, A61K38/385, A61K47/643